Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc. (COEP) reported total sales of $1.4M for FY2025 ending December 31, 2025, primarily from lead generation and webinar services via its NexGenAI technology platform acquired in December 2024, compared to $0 in FY2024. Gross profit was $1.2M, yielding a strong gross margin driven by low cost of goods at $181K. However, total operating expenses rose to $14.2M from $10.1M in FY2024, due to higher professional services ($7.8M), salary ($1.7M), and amortization ($1.0M), resulting in an operating loss of -$13.0M, widened from prior year. Other income netted $766K, including $1.1M gain from derivative liabilities change. Net loss was -$12.3M, or -$11.9M attributable to common stockholders, versus -$10.9M in FY2024; basic EPS was -$3 on 4.2M weighted shares. Balance sheet strengthened with cash at $5.7M (up from $533K), total assets $16.2M, and equity $14.1M. Operating cash use was -$8.6M, offset by $13.7M financing proceeds including $5.5M preferred stock and $4.6M common shares. Biopharma pipeline remains preclinical; pending Z Squared merger signals strategic shift. Going concern doubt persists amid losses and funding needs.

Key Takeaways